This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pardo, L. A. Articles by Stühmer, W. Search for Related Content PubMed PubMed Citation Articles by Pardo, L. A. Articles by Stühmer, W. Related Collections Cellular Pathobiology: Proliferation, Senescence, and Death Therapeutics and Targets Therapeutics and Targets: Identification, Validation, and Markers

Eag1: An Emerging Oncological Target

Max-Planck Institute of Experimental Medicine, Göttingen, Germany

Requests for reprints: Luis A. Pardo, Max-Planck Institute of Experimental Medicine, Hermann-Rein Strasse 3, 37075 Göttingen, Germany. Phone: 49-551-389-9643; Fax: 11-49-551-3899-644; E-mail: pardo{at}em.mpg.de.

Key Words: Eag1 • Potassium channels • Ether a go-go

Emerging evidence indicates that ion channels act in a variety of physiologic and pathologic processes beyond electronic signal transmission, including in cancer. We recently found that the potassium channel Eag1 can mediate cancer progression and that a monoclonal antibody, which inhibits Eag1 action, can effectively restrict cancer cell proliferation. We discuss how Eag1 targeting may be useful in diagnostic or therapeutic settings. [Cancer Res 2008;68(6):1611–3]

This article has been cited by other articles:

				H. C. Hartzell, K. Yu, Q. Xiao, L.-T. Chien, and Z. Qu Anoctamin/TMEM16 family members are Ca2+-activated Cl\#8722; channels J. Physiol., May 15, 2009; 587(10): 2127 - 2139. [Abstract] [Full Text] [PDF]